Pfizer Inc. $PFE Shares Acquired by Mackenzie Financial Corp

Mackenzie Financial Corp increased its holdings in shares of Pfizer Inc. (NYSE:PFE) by 119.6% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 3,106,644 shares of the biopharmaceutical company’s stock after acquiring an additional 1,691,773 shares during the period. Mackenzie Financial Corp’s holdings in Pfizer were worth $79,157,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of the business. Fiduciary Alliance LLC boosted its position in Pfizer by 46.4% during the third quarter. Fiduciary Alliance LLC now owns 145,263 shares of the biopharmaceutical company’s stock worth $3,701,000 after acquiring an additional 46,043 shares during the last quarter. Y Intercept Hong Kong Ltd acquired a new stake in Pfizer in the 3rd quarter valued at about $3,019,000. Vista Investment Partners LLC lifted its stake in Pfizer by 236.1% in the 3rd quarter. Vista Investment Partners LLC now owns 69,613 shares of the biopharmaceutical company’s stock worth $1,774,000 after purchasing an additional 48,900 shares in the last quarter. Money Concepts Capital Corp boosted its holdings in shares of Pfizer by 29.9% during the 3rd quarter. Money Concepts Capital Corp now owns 248,251 shares of the biopharmaceutical company’s stock worth $6,325,000 after purchasing an additional 57,188 shares during the last quarter. Finally, Generali Investments CEE investicni spolecnost a.s. boosted its holdings in shares of Pfizer by 76.4% during the 3rd quarter. Generali Investments CEE investicni spolecnost a.s. now owns 109,269 shares of the biopharmaceutical company’s stock worth $2,784,000 after purchasing an additional 47,319 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Price Performance

Shares of PFE opened at $27.30 on Thursday. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $27.94. The stock has a market cap of $155.24 billion, a PE ratio of 20.07 and a beta of 0.47. The firm has a 50-day simple moving average of $26.43 and a two-hundred day simple moving average of $25.50. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.16 and a quick ratio of 0.87.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share for the quarter, topping analysts’ consensus estimates of $0.57 by $0.09. The business had revenue of $17.56 billion for the quarter, compared to analyst estimates of $16.93 billion. Pfizer had a return on equity of 20.48% and a net margin of 12.42%.The company’s revenue was down 1.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.63 earnings per share. As a group, analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, March 6th. Investors of record on Friday, January 23rd were issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 6.3%. The ex-dividend date of this dividend was Friday, January 23rd. Pfizer’s dividend payout ratio is currently 126.47%.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the company. Argus raised Pfizer from a “hold” rating to a “buy” rating and set a $35.00 price target for the company in a report on Monday, March 2nd. BMO Capital Markets reissued an “outperform” rating and set a $30.00 price target on shares of Pfizer in a research report on Monday. Daiwa Securities Group cut shares of Pfizer from an “outperform” rating to a “neutral” rating and set a $27.00 price objective for the company. in a research report on Thursday, February 12th. Royal Bank Of Canada assumed coverage on shares of Pfizer in a report on Tuesday, February 24th. They issued an “underperform” rating and a $25.00 target price on the stock. Finally, UBS Group assumed coverage on shares of Pfizer in a report on Tuesday, January 6th. They set a “neutral” rating and a $25.00 price target for the company. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, fourteen have issued a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $28.05.

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: China approved Pfizer’s GLP‑1 weight‑management drug Xianweiying for long‑term use in overweight/obese adults — opens a large new commercial market and intensifies competition in the GLP‑1 class, supporting upside to revenue growth if launch execution is strong. Pfizer’s Weight Management Drug Wins China Approval
• Positive Sentiment: Pfizer completed a Phase 2 toddler study for its next‑generation pneumococcal vaccine — a positive clinical read that advances a pipeline asset with potential to drive future vaccine revenues and support longer‑term growth. Pfizer Advances Next-Gen Pneumococcal Vaccine With Completed Phase 2 Toddler Study
• Neutral Sentiment: Pfizer commentary on regulatory agility — company regulatory lead outlines strategies to navigate shifting approval environments; useful for long‑term program risk management but unlikely to move the stock near‑term. Be nimble, be ready: how to tackle regulatory uncertainty in clinical trials
• Neutral Sentiment: Valuation pieces (Yahoo/Seeking Alpha) debate whether Pfizer’s current price captures post‑pandemic pipeline and patent risks — these analyses reinforce mixed investor views: stable cash flows and dividends vs. legacy product cliffs and pipeline uncertainty. Does Pfizer (PFE) Offer Value After Post Pandemic Pipeline And Patent Concerns
• Negative Sentiment: Patent/legal developments in the sector affected peers and related stocks — a patent “shake‑up” around tafamidis helped BridgeBio trade higher, illustrating ongoing IP risk and competitive uncertainties that can indirectly pressure Pfizer where patent battles exist. Why BridgeBio Leapfrogged Its 50-Day Line On Pfizer’s Patent Shake-Up
• Negative Sentiment: Sector headlines (e.g., BioNTech leadership changes) are creating rotation and volatility in vaccine/biotech names; while not directly about Pfizer, this can weigh on sentiment for large pharma stocks during risk‑off moves. BioNTech Cofounders To Step Down. Stock Crumbles.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.